Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
Baidu Shares Surge as Company Plans Kunlunxin AI Chip Spin-Off and Hong Kong Listing 
Reddit Emerges as a Major Winner in the Shift to AI-Powered Search 
Tesla Poised for Breakout Year in 2026 as New Products and EV Market Reset Drive Growth 
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support 
NextEra Energy Stock Rises After Reaffirming Earnings and Dividend Growth Outlook 
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration 
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
Google Accelerates AI Infrastructure With Ironwood TPU Expansion in 2026 
Grok AI Faces Global Scrutiny Over Safeguard Failures and Illegal Content on X 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change 
NEW YORK, April 01, 2016 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Rockwell Medical, Inc. (“Rockwell” or the “Company”) (Nasdaq:RMTI) between September 9, 2015 and February 29, 2016.
You are hereby notified that a securities class action has been commenced in the USDC for the Southern District of New York. If you purchased or otherwise acquired Rockwell securities between September 9, 2015 and February 29, 2016, your rights may be affected by this action. To get more information go to: http://www.zlk.com/pslra/rockwell-medical.
The complaint alleges that the Company failed to disclose that: (1) Rockwell’s main product offering for Triferic has not yet been approved by the FDA; and (2) Rockwell is seeking to obtain transitional add-on payment reimbursement for Triferic with the Centers for Medicare & Medicaid Services instead of bundled reimbursement.
If you suffered a loss in Rockwell you have until May 3, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://www.zlk.com/pslra/rockwell-medical.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Eduard Korsinsky, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
